← Back to Search

Behavioral Intervention

Neuromodulation + Neurorehabilitation for Concussion + PTSD

N/A
Waitlist Available
Led By Theresa LB Pape, Dr.PH
Research Sponsored by Theresa Pape
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 18 years of age and no older than 60 years of age
3 months to 10 years post exposure to mTBI event
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 5 weeks, 10 weeks, 20 weeks
Awards & highlights

Study Summary

This trial will study the effects of a common computer attention processing training combined with transcranial magnetic stimulation on the attention systems of people with brain injuries and PTSD.

Who is the study for?
This trial is for adults aged 18-60 who have experienced a mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) between 3 months to 10 years ago. Candidates must be fluent in English, not involved in other studies, without epilepsy or severe heart conditions, not pregnant, and free from certain metal implants that affect MRI or TMS procedures.Check my eligibility
What is being tested?
The study tests the combined effect of attention processing training (APT) with intermittent theta burst stimulation (iTBS), against placebos for each treatment. It aims to assess improvements in attention among those with mTBI plus PTSD and understand changes in their neurocognitive systems.See study design
What are the potential side effects?
Potential side effects may include discomfort at the stimulation site, headache, lightheadedness during iTBS sessions. There's also a low risk of seizure due to magnetic stimulation but precautions are taken to minimize this.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 60 years old.
Select...
I experienced a mild traumatic brain injury between 3 months and 10 years ago.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 5 weeks, 10 weeks, 20 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 5 weeks, 10 weeks, 20 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the Mayo Portland Adaptability Inventory (MPAI)
Secondary outcome measures
change in the PTSD Checklist (PCL)

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: real APT+ real iTBSExperimental Treatment2 Interventions
real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
Group II: placebo APT+ real iTBSActive Control2 Interventions
30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
Group III: real APT + placebo iTBSActive Control2 Interventions
30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
Group IV: placebo APT+ placebo iTBSActive Control2 Interventions
30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.

Find a Location

Who is running the clinical trial?

Theresa PapeLead Sponsor
Theresa LB Pape, Dr.PHPrincipal InvestigatorEdward Hines Jr. VA Hospital

Media Library

APT (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT03819608 — N/A
Post-Traumatic Stress Disorder Research Study Groups: placebo APT+ real iTBS, real APT + placebo iTBS, placebo APT+ placebo iTBS, real APT+ real iTBS
Post-Traumatic Stress Disorder Clinical Trial 2023: APT Highlights & Side Effects. Trial Name: NCT03819608 — N/A
APT (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03819608 — N/A
~43 spots leftby Jun 2025